Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 174 results for "julie masow"

U.S. seeks up to $3.35 billion in Novartis kickback lawsuit
Investing.com

U.S. seeks up to $3.35 billion in Novartis kickback lawsuit

NEW YORK, June 30 (Reuters) - The United States says Novartis AG should pay as much as $3.35 billion in damages and civil fines because the Swiss drugmaker used kickbacks to boost sales of two drugs covered by Medicare and Medicaid. In ... CNBC, 21 hours ago
[x]  

Unions accuse Novartis of 'sham' patent fight to delay Sun's Gleevec generics

'; if(pArray.length >= 4) { i=2; } else if(pArray.length >= 3) { i=2; inline = ''; } else if(pArray.length >= 2) { i=1; inline = ''; } else if(pArray.length === 1) { i=0; inline = ''; } $('#librarydrawer_story_container script').each(function() { ...
 FiercePharma5 days ago
USA Today

Skyrocketing drug prices leave cures out of reach for some patients

UP NEXT 03 Doctors and researchers are excited about new therapies derived from the study of the human genome that hold the promise of curing multiple forms of cancer using the patients own DNA to undo cancer cells. Mary Lee, USA TODAY Many ...
 USA Today2 weeks ago

Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder

/PRNewswire/ --Novartis announced today that the US Food and Drug Administration (FDA) has approved Promacta ® (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient ...
 Industrial Info Financials2 weeks ago 6/11/15 - Novartis gains FDA approval for Promacta® providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder  Pharmacy Choice2 weeks ago
[x]  

Novartis presents new data at WCD that shows significant efficacy of Cosentyx® in patients with psoriasis of the palms, soles of feet and nails

/PRNewswire/ --Novartis announced today that Cosentyx ® (secukinumab) met the primary endpoints in two new clinical studies, showing superior efficacy compared to placebo in patients with psoriasis of the palms, soles of feet and nails, all of ...
 Industrial Info Financials2 weeks ago
[x]  

Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma

/PRNewswire/ -- Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat ...
 Bloomberg4 weeks ago
[x]  

Novartis presents new data at ASCO for Zykadia and combination of Tafinlar® and Mekinist® in certain NSCLC patients with unmet needs

/PRNewswire/ --Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar ® (dabrafenib) in combination with Mekinist ® (trametinib) in certain patients with non-small cell lung ...
 Reliance Trust4 weeks ago
[x]  

Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma

/PRNewswire/ -- Novartis today announced data from the Phase III COMBI-d study showing a significant survival benefit for patients with BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar ® (dabrafenib) ...
 Franklin Credit Management Corporation1 month ago
[x]  

Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA

/PRNewswire/ --Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual ...
 RCL Advisors1 month ago
[x]  

Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies

/PRNewswire/ -- Today,Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In the ...
 Tamar Securities1 month ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less